GlucoLight Corporation Successfully Completes First Hypoglycemic ''Clamping'' Study of Sentris-100(TM)
BETHLEHEM, Pa.--(BUSINESS WIRE)--GlucoLight Corporation, a development-stage company focused on blood glucose monitoring in the acute care environment, today announced the successful conclusion of the company’s first hypoglycemic “clamping” study to evaluate its continuous, non-invasive glucose monitor, Sentris-100™.